Impact of MRI surveillance and breast cancer detection in young women with BRCA mutations

Annals of Oncology

Volumn 22, Issue SUPPL. 1, 2011, Pages

  Warner, E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

BRCA; Hereditary breast cancer; Magnetic resonance imaging; Psychosocial issues; Surveillance; Young women

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DENOSUMAB; DOXORUBICIN; ESTROGEN; FLUOROURACIL; GONADORELIN; METHOTREXATE; PROGESTERONE; RISEDRONIC ACID; TAMOXIFEN; TRASTUZUMAB; ZOLEDRONIC ACID;

AGE DISTRIBUTION; AMENORRHEA; ARTICLE; ATTITUDE TO HEALTH; AWARENESS; BONE DENSITY; BRCA GENE; BREAST CANCER; BREAST EXAMINATION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CANCER STAGING; CRYOPRESERVATION; EARLY DIAGNOSIS; EARLY MENOPAUSE; ESTROGEN BLOOD LEVEL; FEMALE INFERTILITY; GENE MUTATION; HUMAN; JAW OSTEONECROSIS; KIDNEY DEVELOPMENT; MAMMOGRAPHY; MASTECTOMY; MICROMETASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; OVARIECTOMY; PREMATURE OVARIAN FAILURE; PREVALENCE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROGNOSIS; QUALITY OF LIFE; RISK REDUCTION; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SOCIAL BEHAVIOR; SOCIAL CARE; SOCIAL INTERACTION; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; SYMPTOM; TERATOGENESIS; TREATMENT CONTRAINDICATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADULT; AGE FACTORS; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC;

EID: 79551638378     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq665     Document Type: Article

References (54)

1. Ford D, Easton DF, Stratton M. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 676-689.
2. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 15: 1329-1333.
3. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J. et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008; 122: 2017-2022.
4. Brekelmans CTM, Seynaeve C, Bartels CCM. et al. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. J Clin Oncol 2001; 19: 924-930.
5. Scheuer L, Kauff N, Robson M. et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002; 20: 1260-1268.
6. Vasen HFA, Tesfay E, Bonnstra H. et al. Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer 2004; 41: 549-554.
7. Komenaka IK, Ditkoff B, Joseph K. et al. The development of interval breast malignancies in participants with BRCA mutations. Cancer 2004; 100: 2079-2083.
8. Sardanelli F, Podo F, D'Agnolo G. et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology 2007; 242: 698-715.
9. Warner E, Messersmith H, Causer P. et al. Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 2008; 148: 671-679.
10. Warner E, Plewes DB, Hill KA. et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292: 1317-1325.
11. Lehman C, Blume JD, Weatherall P. et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005; 103: 1898-1905.
12. Kriege M, Brekelmans CTM, Boetes C. et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 427-437.
13. Kuhl CK, Schrading S, Leutner CC. et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23: 8469-8476.
14. Leach MO, Boggis GRM, Dixon AK. et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2006; 365: 1769-1778.
15. Lehman CD, Isaacs C, Schall MD. et al. Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology 2007; 244: 381-388.
16. Hagen AI, Kvistad KA, Maehle L. et al. Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 2007; 16: 367-374.
17. Warner E, Plewes DB, Shumak RS. et al. Comparison of breast magnetic resonance imaging, mammgoraphy, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001; 19: 3524-3531.
18. Trecate G, Verhanaghi D, Manoukian S. et al. MRI in the early detection of breast cancer in women with high genetic risk. Tumori 2006; 92: 517-523.
19. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101: 80-87.
20. Narod SA, Brunet J-S, Ghadirian P. et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet 2000; 356: 1876-1881.
21. Tilanus-Linthorst MMA, Obdeijn I-M, Hop WCJ. et al. A BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, UK, and Canadian MRI screening trials. Clin Cancer Res 2007; 13: 7357-7362.
22. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2009; 28: 222-231.
23. Avis NE, Crawford S, Manuel J. Quality of life among younger women with breast cancer. J Clin Oncol 2005; 23: 3322-3330.
24. De Bree E, Makrigiannakis A, Askorxylakis J. et al. Pregnancy after breast cancer: a comprehensive review. J Surg Oncol 2010; 101: 534-542.
25. Kroman N, Jensen MB, Wohlfahrt J. et al. Pregnancy after treatment of breast cancer-a population-based study on behalf of the Danish Breast Cancer Cooperative Group. Acta Oncol 2008; 47: 545-549.
26. Ives A, Sunders C, Bulsara M. et al. Pregnancy after breast cancer: population based study. BMJ 2007; 334: 194.
27. Lee SJ, Schover LR, Patridge AH. et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917-2931.
28. Goldhirsch A, Ingle JN, Gelber RD. et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
29. Partridge AH, Gelber S, Peppercorn J. et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004; 22: 4174-4183.
30. Quinn GP, Vadaparampil ST, Lee J-H. et al. Physician referral for fertility preservation in oncology patients: a national study of practice behaviours. J Clin Oncol 2009; 27: 5952-5957.
31. Lohrisch C, Paltiel C, Glemon K. et al. Impact on survival of time from definitive surgery to initiation of ajuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2006; 24: 4888-4894.
32. Oktay K, Buyuk E, Libertella N. et al. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 2005; 23: 4347-4353.
33. Porcu E, Bazzocchi A, Notarengelo L. et al. Human oocyte crypreservation in infertility and oncology. Curr Opin Endocrinol Diabetes Obes 2008; 15: 529-535.
34. Oktay K, Kim JY, Barad D. et al. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 2010; 28: 240-244.
35. Hulvat MC, Jeruss JS. Maintaining fertility in young women with breast cancer. Curr Treat Options Oncol 2009; 10: 308-317.
36. Gnant MF, Mlineritsch B, Ebengreuth GL. et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Study Group. J Clin Oncol 2007; 25: 820-828.
37. Vehmanen L, Saarto T, Elomaa. et al. Long-term impact of chemotherapyinduced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 2001; 37: 2373-2378.
38. Hines SL, Mincey BA, Sloan JA. et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 2008; 27: 1047-1053.
39. Patel V, McLeod NM, Rogers SN. Bisphosphonate osteonecrosis of the jawa literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention. Br J Oral Maxillofac Surg 201; Jun 2 [Epub ahead of print].
40. Aghaloo Tal, Feisenfeld AL, Tdtradis S. Osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg 2010; 68: 959-963.
41. Hahn KME, Johnson PH, Gordon N. et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 2006; 107: 1219-1226.
42. Johannsson O, Loman N, Borg A, Olsson H. Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet 1998; 352: 1350-1351.
43. Andrieu N, Goldgar DE, Easton DE. et al. Pregnancies, breast-feeding, and breast cancer risk in the international BRCA1/2 carrier cohort study (IBCCS). J Nat Cancer Inst 2006; 98: 535-544.
44. Mondi MM, Cuenca RE, Ollila DW. et al. Sentinel lymph node biopsy during pregnancy: initial clinical experience. Ann Surg Oncol 2007; 14: 218-221.
45. Mir O, Beveiller P, Ropert S. et al. Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol 2008; 19: 607-613.
46. Ring AE, Smith IE, Jones A. et al. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol 2005; 23: 4192-4197.
47. Lethaby AE, O'Neill MA, Mason BH. et al. Overall survival from breast cancer in women pregnant or lactating at or after diagnosis. Int J Cancer 1996; 76: 751-755.
48. Ezzat A, Raja MA, Berry J. et al. Impact of pregnancy on non-metastatic breast cancer: a case control study. Clin Oncol 1996; 8: 367-370.
49. Warr DG, Street JC, Carides AD. et al. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant of patients receiving adriamycincyclophosphamide-based chemotherapy. Support Care Cancer 2010; May 13 [Epub ahead of print].
50. Rowland JH, Meyerowitz BE, Crespi CM. et al. Addressing intimacy and partner communication after breast cancer: a randomized controlled group intervention. Breast Cancer Res Treat 2009; 118: 99-111.
51. Hilton BA, Crawford JA, Tarko MA. Men's perspective on individual and family coping with their wives' breast cancer and chemotherapy. West J Nurs Res 2000; 22: 428-459.
52. Kayser K, Sormanti M. A follow-up study of women with cancer: their psychosocial well-being and close relationships. Social Work Health Care 2002; 35: 391-406.
53. Avis NE, Crawford S, Manuel J. Psychosocial problems among younger women with breast cancer. Psycho-oncology 2004; 13: 295-308.
54. Skerrett K. Couple adjustment to the experience of breast cancer. Fam Syst Health 1998; 16: 281-298.